Selected Publications
Kleitsch, J., Weiner, J.D., Pandya, R. et al: The physical and emotional impact of cutaneous dermatomyositis: a qualitative study Arch Dermatol Res 315 (8): 2431-2435,2023.
Dan J, Sprow G, Concha J, Patel J, Kodali N, Diaz D, Vazquez T, Werth VP.: A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis Br J Dermatol 189 (2): 227-228,2023.
Pandya R, Dan J, Kleitsch J, White B, Werth VP.: Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial J Invest Dermatol (23): 2023.
Desai AD, Werth VP, Elman SA.: Characterizing primary hospitalizations for systemic lupus erythematosus in the United States Rheumatology (Oxford) 12 : 290,2023.
Dan J, Sprow G, Concha J, Patel J, Kodali N, Diaz D, Vazquez T, Werth VP: A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis Br J Dermatol 189 (2): 227-228,2023.
Yale M, Dunn P, Strong R, Davies I, Gallu L, Joly P, Murrell DF, Werth VP, Payne AS: The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid J Invest Dermatol S0022-202X (23): 01971-1,2023.
Cordel N, Dechelotte B, Jouen F, Lamb JA, Chinoy H, New P, Vencovsky J, Mann H, Galindo-Feria AS, Dani L, Selva-O'Callaghan A, Werth VP, Ravishankar A, Landon-Cardinal O, Tressières B, Boyer O: Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study Rheumatology (Oxford) 62 (4): 1711-1715,2023.
Pandya R, Kleitsch J, Werth VP: Trial of intravenous immune globulin in dermatomyositis: a critically appraised research paper Br J Dermatol 188 (6): 738-739,2023.
García-Romero MT, Tollefson M, Pope E, Brandling-Bennett HA, Paller AS, Keimig E, Arkin L, Wanat KA, Humphrey SR, Werth VP, Oza V, Jacobe H, Fett N, Cordoro KM, Medina-Vera I, Chiu YE: Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea JAMA Dermatol 159 (3): 299-307,2023.
Morand E, Pike M, Merrill JT, Van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Shah V, Sharkey B, Wegman T, Ctlett I, Banerjee S, Singhal S: Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus rythematosus: a phase 2, randomized, double-blind, placebo-controlled study Arthritis Rheumatol 75 (2): 242-252,2023.
Academic Contact Information
Division of Dermatology
Veterans Administration Hospital
University and Woodland Avenues
Philadelphia,
PA
19104
Phone: 215-823-4208
Patient appointments: 800-789-7366